Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.